Professor Gouri Shankar Bhattacharyya

por Zielinski, C.
Publicado 2021

ESMO Clinical Practice Guidelines: adapting and adopting new approaches for development, implementation and audit

por Pentheroudakis, G., Curigliano, G., Zielinski, C.
Publicado 2022

Introducing pro and con discussions in ESMO Open—Cancer Horizons

por Zielinski, C., Preusser, M., Berghoff, A.
Publicado 2022

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer

por Zielinski, C., Knapp, S., Mascaux, C., Hirsch, F.
Publicado 2013

Two types of human Th17 cells with pro- and anti-inflammatory properties and distinct roles in autoinflammation

por Noster, R, de Koning, H, Sallusto, F, Zielinski, C
Publicado 2015

Decreased production of soluble interleukin 2 receptor by phytohaemagglutinin-stimulated peripheral blood mononuclear cells in patients with breast cancer after adjuvant therapy.

por Zielinski, C. C., Müller, C., Tichatschek, E., Aiginger, P.
Publicado 1989

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.

por Zielinski, C. C., Schnack, B., Grbovic, M., Brodowicz, T., Wiltschke, C., Steger, G., Pflüger, H., Marberger, M.
Publicado 1998

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

por Vogl, U M, Zehetgruber, H, Dominkus, M, Hejna, M, Zielinski, C C, Haitel, A, Schmidinger, M
Publicado 2006

Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-α and retinoids

por Brodowicz, T, Wiltschke, C, Kandioler-Eckersberger, D, Grunt, T W, Rudas, M, Schneider, S M, Hejna, M, Budinsky, A, Zielinski, C C
Publicado 1999

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status

por Brodowicz, T, Kandioler, D, Tomek, S, Ludwig, C, Rudas, M, Kunstfeld, R, Koestler, W, Hejna, M, Budinsky, A, Wiltschke, C, Zielinski, C C
Publicado 2001

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center

por Füreder, L. M., Widhalm, G., Gatterbauer, B., Dieckmann, K., Hainfellner, J. A., Bartsch, R., Zielinski, C. C., Preusser, M., Berghoff, A. S.
Publicado 2018

Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study.

por Wiltschke, C., Krainer, M., Budinsky, A. C., Berger, A., Müller, C., Zeillinger, R., Speiser, P., Kubista, E., Eibl, M., Zielinski, C. C.
Publicado 1995

Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCAmutations

por Wagner, T M U, Möslinger, R, Langbauer, G, Ahner, R, Fleischmann, E, Auterith, A, Friedmann, A, Helbich, T, Zielinski, C, Pittermann, E, Seifert, M, Oefner, P
Publicado 2000

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatm...

por Hudelist, G, Köstler, W J, Attems, J, Czerwenka, K, Müller, R, Manavi, M, Steger, G G, Kubista, E, Zielinski, C C, Singer, C F
Publicado 2003

Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors

por Berghoff, A S, Bago-Horvath, Z, Ilhan-Mutlu, A, Magerle, M, Dieckmann, K, Marosi, C, Birner, P, Widhalm, G, Steger, G G, Zielinski, C C, Bartsch, R, Preusser, M
Publicado 2012

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers

por Cherny, N I, Sullivan, R, Dafni, U, Kerst, J M, Sobrero, A, Zielinski, C, Piccart, M J, Bogaerts, J, Tabernero, J, Latino, N J, de Vries, E G E
Publicado 2016

Prognostic impact of breast cancer subtypes in elderly patients

por Bergen, E. S., Tichy, C., Berghoff, A. S., Rudas, M., Dubsky, P., Bago-Horvath, Z., Mader, R. M., Exner, R., Gnant, M., Zielinski, C. C., Steger, G. G., Preusser, M., Bartsch, R.
Publicado 2016

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia

por Heller, G, Topakian, T, Altenberger, C, Cerny-Reiterer, S, Herndlhofer, S, Ziegler, B, Datlinger, P, Byrgazov, K, Bock, C, Mannhalter, C, Hörmann, G, Sperr, W R, Lion, T, Zielinski, C C, Valent, P, Zöchbauer-Müller, S
Publicado 2016

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

por Bartsch, R, Berghoff, A, Pluschnig, U, Bago-Horvath, Z, Dubsky, P, Rottenfusser, A, DeVries, C, Rudas, M, Fitzal, F, Dieckmann, K, Mader, R M, Gnant, M, Zielinski, C C, Steger, G G
Publicado 2012

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

por Brodowicz, T, Lang, I, Kahan, Z, Greil, R, Beslija, S, Stemmer, S M, Kaufman, B, Petruzelka, L, Eniu, A, Anghel, R, Koynov, K, Vrbanec, D, Pienkowski, T, Melichar, B, Spanik, S, Ahlers, S, Messinger, D, Inbar, M J, Zielinski, C
Publicado 2014